ICER favours vinorelbine + cisplatin for NSCLC

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.534, 2007-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine plus vinorelbine superior in NSCLC

Inpharma, Vol. 1, Iss. 1251, 2000-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Gemcitabine plus cisplatin for NSCLC

Inpharma, Vol. 1, Iss. 1222, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment

By Caffo Orazio Dipasquale Mariachiara Murgia Viviana Veccia Antonello Galligioni Enzo

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1037-1051

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel/vinorelbine similar to paclitaxel/carboplatin in NSCLC

Inpharma, Vol. 1, Iss. 1450, 2004-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Docetaxel + cisplatin active in advanced NSCLC

Inpharma, Vol. 1, Iss. 1478, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite